148 related articles for article (PubMed ID: 37096376)
1. Two-Year Changes in Diabetic Kidney Disease Phenotype and the Risk of Heart Failure: A Nationwide Population-Based Study in Korea.
Lee SE; Yoo J; Choi HS; Han K; Kim KA
Diabetes Metab J; 2023 Jul; 47(4):523-534. PubMed ID: 37096376
[TBL] [Abstract][Full Text] [Related]
2. Hip Fracture Risk According to Diabetic Kidney Disease Phenotype in a Korean Population.
Lee SE; Yoo J; Kim KA; Han K; Choi HS
Endocrinol Metab (Seoul); 2022 Feb; 37(1):148-158. PubMed ID: 35255607
[TBL] [Abstract][Full Text] [Related]
3. The risk of Parkinson's disease according to diabetic kidney disease status in a Korean population.
Lee SE; Yoo J; Choi HS; Han K; Kim KA
Parkinsonism Relat Disord; 2022 Jul; 100():13-18. PubMed ID: 35667188
[TBL] [Abstract][Full Text] [Related]
4. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
[TBL] [Abstract][Full Text] [Related]
5. The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study.
Lee SE; Yoo J; Kim BS; Choi HS; Han K; Kim KA
Diabetol Metab Syndr; 2023 Mar; 15(1):32. PubMed ID: 36855144
[TBL] [Abstract][Full Text] [Related]
6. 2023 Diabetic Kidney Disease Fact Sheet in Korea.
Kim NH; Seo MH; Jung JH; Han KD; Kim MK; Kim NH
Diabetes Metab J; 2024 May; 48(3):463-472. PubMed ID: 38499437
[TBL] [Abstract][Full Text] [Related]
7. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study.
Lee YB; Kim DH; Kim SM; Kim NH; Choi KM; Baik SH; Park YG; Han K; Yoo HJ
Cardiovasc Diabetol; 2020 Jun; 19(1):77. PubMed ID: 32534576
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in patients with type 2 diabetes mellitus-related kidney disease: A Jordanian population cohort study.
Farah R; Alhajahjeh A; Nofal A; Hyasat TB; Abu Jabeh RAH; Suboh LT; Alhawari H; Momani MS; Jaber HJ; AlAwwa I
J Diabetes Complications; 2023 Jun; 37(6):108478. PubMed ID: 37084653
[TBL] [Abstract][Full Text] [Related]
10. A study of the natural history of diabetic kidney disease (DKD).
Altemtam N; Russell J; El Nahas M
Nephrol Dial Transplant; 2012 May; 27(5):1847-54. PubMed ID: 22058177
[TBL] [Abstract][Full Text] [Related]
11. The Prognosis of Patients With Type 2 Diabetes and Nonalbuminuric Diabetic Kidney Disease Is Not Always Poor: Implication of the Effects of Coexisting Macrovascular Complications (JDDM 54).
Yokoyama H; Araki SI; Kawai K; Yamazaki K; Shirabe SI; Sugimoto H; Minami M; Miyazawa I; Maegawa H;
Diabetes Care; 2020 May; 43(5):1102-1110. PubMed ID: 32144168
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW
J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584
[TBL] [Abstract][Full Text] [Related]
13. Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A
Cherney DZI; Dagogo-Jack S; Cosentino F; Pratley RE; Frederich R; Maldonado M; Liu CC; Cannon CP
Kidney Int Rep; 2022 Aug; 7(8):1782-1792. PubMed ID: 35967112
[TBL] [Abstract][Full Text] [Related]
14. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
15. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study.
Penno G; Solini A; Orsi E; Bonora E; Fondelli C; Trevisan R; Vedovato M; Cavalot F; Zerbini G; Lamacchia O; Nicolucci A; Pugliese G;
BMC Med; 2021 Mar; 19(1):66. PubMed ID: 33715620
[TBL] [Abstract][Full Text] [Related]
17. Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study.
Cid Ruzafa J; Paczkowski R; Boye KS; Di Tanna GL; Sheetz MJ; Donaldson R; Breyer MD; Neasham D; Voelker JR
Int J Clin Pract; 2015 Aug; 69(8):871-82. PubMed ID: 26011029
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiovascular disease, death, and renal progression in diabetes according to albuminuria and estimated glomerular filtration rate.
Niu J; Zhang X; Li M; Wu S; Zheng R; Chen L; Huo Y; Xu M; Wang T; Zhao Z; Wang S; Lin H; Qin G; Yan L; Wan Q; Chen L; Shi L; Hu R; Tang X; Su Q; Yu X; Qin Y; Chen G; Gao Z; Wang G; Shen F; Luo Z; Chen Y; Zhang Y; Liu C; Wang Y; Wu S; Yang T; Li Q; Mu Y; Zhao J; Bi Y; Ning G; Wang W; Lu J; Xu Y;
Diabetes Metab; 2023 Mar; 49(2):101420. PubMed ID: 36640827
[TBL] [Abstract][Full Text] [Related]
19. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018.
Guo W; Song Y; Sun Y; Du H; Cai Y; You Q; Fu H; Shao L
Front Endocrinol (Lausanne); 2022; 13():1071465. PubMed ID: 36561561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
